Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty

Bcr-Abl

The Bcr/Abl fusion protein is localized to the cytoplasm and actin cytoskeleton of hematopoietic cells, and has increased and dysregulated tyrosine kinase activity.

  • MBM-55S
    T119612083624-07-9In house
    MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer cells. MBM-55S shows antitumor activities.
    • $195
    In Stock
    Size
    QTY
  • AN-019
    T26625879507-25-2In house
    AN-019 (NRC-019) is a Bcr-Abl kinase inhibitor with antitumor activity for the study of chronic myelogenous leukemia (CML) and breast cancer.
    • $293 TargetMol
    In Stock
    Size
    QTY
  • CpCDPK1/TgCDPK1-IN-1
    T786051092788-23-2In house
    CpCDPK1/TgCDPK1-IN-1 is a potent dual inhibitor of CpCDPK1 and TgCDPK1, inhibits Abl and Src, and has antiparasitic activity for the study of Toxoplasma infections and cryptosporidiosis.
    • $350
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Imatinib impurities3
    T67847404844-11-7
    Imatinib impurities3 is a protein kinases inhibitor with IC50 values of 6.95uM, 0.245uM, 0.139uM for ABL1 wt, KIT wt, PDGFRR wt, respectively.
    • $40
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • PF-06651481-00
    T283741391063-17-4
    PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.
    • $79
    In Stock
    Size
    QTY
  • PPY A
    T23182875634-01-8
    PPY A is a potent inhibitor of T315l mutant and wild-type Abl kinase (IC50 of 9 and 20 nM, respectively).PPY A also inhibits the growth of Bcr-Abl T315l mutant or wild-type Bcr-Abl genetically transformed cells.
    • $158
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • CGP77675
    T30855234772-64-6In house
    CGP77675 (ZINC1488120) is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and autophosphorylation of purified Src. CGP77675 exhibits anticancer activity.
    • $43
    In Stock
    Size
    QTY
  • SKLB 1028
    T346561350544-93-2In house
    SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants.
    • $51
    In Stock
    Size
    QTY
  • Cenisertib
    T14925871357-89-0In house
    Cenisertib is A potent ATP-competitive multi-kinase inhibitor, showing inhibitory effects on the activity of Aurora-kinase-A/B, ABL1, AKT, STAT5, FLT3, as well as kinase inhibitors of FER and its homolog. Cenisertib inhibits the growth of tumor mast cells (MCS) by inhibiting the activity of several different molecular targets. Cenisertib also inhibits tumor growth in pancreatic, breast, colon, ovarian and lung cancer and leukemia in xenograft models.
    • $987
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Vamotinib
    T637461416241-23-0In house
    Vamotinib (PF-114) is an orally active and specific tyrosine kinase inhibitor with antiproliferative and antitumour activity.Vamotinib inhibits the phosphorylation of BCR/ABL and BCR/ABL-T315I, which promotes apoptosis. Vamotinib is used to study drug-resistant Philadelphia chromosome-positive (Ph+) leukaemia and Alzheimer's disease.
    • $133
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • PP1
    T6196172889-26-8
    PP1 (AGL 1872), a specific and effective Src inhibitor, is with IC50 for Lck/Fyn is 5 nM/ 6 nM, respectively.
    • $34
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • AST 487
    T4053630124-46-8
    AST 487 (NVP-AST 487) is a RET kinase inhibitor, inhibiting RET autophosphorylation and activation of downstream effectors. It also can inhibit Flt-3.
    • $31
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • BGG463
    T4618890129-26-7
    BGG463 (K 0859) can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.
    • $56
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Bosutinib
    T0152380843-75-4
    Bosutinib (SKI-606) is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl (IC50: 1 nM) and Src (IC50: 1.2 nM) kinases.
    • $37
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Danusertib
    T2094827318-97-8
    Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed.
    • $54
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Degrasyn
    T6300856243-80-6
    Degrasyn (WP1130) (WP1130), a specific deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor, also inhibits Bcr/Abl, which is a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT).
    • $58
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • PP121
    T24151092788-83-4
    PP-121 is a multi-targeted inhibitor of PDGFR (IC50: 2 nM), Hck (IC50: 8 nM), mTOR (IC50: 10 nM), VEGFR2(IC50: 12 nM), Src (IC50: 14 nM) and Abl (IC50: 18 nM) , also inhibits DNA-PK (IC50: 60 nM).
    • $51
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Imatinib Mesylate
    T1621220127-57-1
    Imatinib Mesylate (STI-571) is a tyrosine kinase receptor inhibitor with antineoplastic activity (IC50s: 0.6 μM, 0.1 μM and 0.1 μM for v-Abl, c-Kit and PDGFR, respectively).
    • $54
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Berbamine dihydrochloride
    T29206078-17-7
    Berbamine dihydrochloride (Berbamine), a natural compound derived from the Berberis amurensis plant, has been shown to exhibit antitumor activity in several Ys.
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Dasatinib monohydrate
    T1448L863127-77-9
    Dasatinib monohydrate (BMS-354825 Monohydrate) is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib monohydrate binds to and inhibits the growth-promoting activities of these kinases. Apparently, because of its less stringent binding affinity for the BCR-ABL kinase, Dasatinib monohydrate has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations.
    • $33
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • AT9283
    T3068896466-04-9
    AT9283 (J-504568) is an effective multi-targeted inhibitor of JAK2(IC50=1.2 nM) and JAK3(IC50=1.1 nM), Aurora A, Aurora B and Abl(T315I).
    • $39
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Bafetinib
    T6311859212-16-1
    Bafetinib (INNO-406) (INNO-406) is an effective and specific dual Bcr-Abl/Lyn inhibitor (IC50: 5.8/19 nM), and no inhibition of the phosphorylation of the T315I mutant and less effective to c-Kit and PDGFR.
    • $31
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • PHA-665752
    T6128477575-56-7
    PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM), >50-fold selectivity for c-Met than STKs or RTKs.
    • $59
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Asciminib
    T51771492952-76-7
    Asciminib (ABL001) (ABL001) is a potent and selective Bcr-Abl inhibitor (Kd: 0.5–0.8nM).
    • $57
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Nocodazole
    T280231430-18-9
    Nocodazole (Oncodazole) is a reversible inhibitor of microtubule polymerization and an inhibitor of Bcr-Abl. Nocodazole has antitumor activity, blocks the cell cycle and induces apoptosis.
    • $31
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Olverembatinib
    T30711257628-77-5
    Olverembatinib (GZD 824) is an orally bioavailable Bcr-Abl inhibitor for Bcr-Abl(WT, IC50: 0.34 nM) and Bcr-Abl(T315I, IC50: 0.68 nM).
    • $30
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Rebastinib
    T26401020172-07-9
    DCC-2036 (Rebastinib (DCC-2036)) is a conformational control Bcr-Abl inhibitor for Abl1(WT, IC50: 0.8 nM) and Abl1(T315I, IC50: 4 nM), also inhibits LYN, SRC, HCK, FGR, FLT3, KDR, and Tie-2, and low activity to c-Kit. Rebastinib aimed at the Angiopoietin2-Tie2 pathway.
    • $40
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Nilotinib
    T1524641571-10-0
    Nilotinib (AMN107) is a second-generation Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
    • $35
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Dasatinib
    T1448302962-49-8
    Dasatinib (BMS-354825) is a tyrosine kinase inhibitor that inhibits Src and Bcr-Abl (Ki=16/30 pM) and is orally active and ATP-competitive. Dasatinib has antitumor activity and is used in the treatment of leukemia and lymphoma.
    • $37
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Imatinib
    T6230152459-95-5
    Imatinib (STI571) is a multi-targeted receptor tyrosine kinase inhibitor that selectively inhibits the kinase activities of BCR/ABL, v-Abl, PDGFR, and c-kit with oral activity. Imatinib has antitumor activity for the treatment of chronic granulocytic leukemia.
    • $36
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • SGX-523
    T22931022150-57-7
    SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p38α, and c-Raf.
    • $44
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Ponatinib
    T2372943319-70-8
    Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor (IC50s: 0.37/1.1/1.5/2.2/5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively).
    • $50
    In Stock
    Size
    QTY
    TargetMol | Citations Cited
  • Multi-kinase inhibitor 1
    T4191778274-97-8
    Multi-kinase inhibitor 1 (Multi-kinase inhibitor I) is a Multi-kinase inhibitor.
    • $33
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AKE-72
    T806762566525-18-4
    AKE-72 is a Pan-BCR-ABL inhibitor with anti-leukemic activity.AKE-72 inhibits the proliferation of Ba/F3 cells expressing natural BCR-ABL or its T315I mutant.
    • $158
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • BCR-ABL-IN-8
    T829091808288-49-4
    BCR-ABL-IN-8 (compound 26f) is a BCR-ABL inhibitor featuring a trimethoxy group [1].
    • Inquiry Price
    Size
    QTY
    TargetMol | Inhibitor Sale
  • AD57
    T22552L1093380-42-7
    AD57 is a potent inhibitor of both c-Src and Abl with IC50 of 0.025 μM and 0.041 μM, respectively.
    • $47
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • Silybin B
    TN2211142797-34-0
    Silybin B (Silibinin B) is an effective inhibitor of raloxifene 4 '- and 6-glucosalylation, an effective anti-fibrinogenic and anti-oligomeric component of Silymarin, with free radical scavenging activity of 1, 1-diphenyl-2-pyridinyl hydrazine (DPPH), and a protective effect against cisplatin-induced neurotoxicity by alleviating DNA damage and apoptosis. Silybin B can inhibit the growth of human chronic myeloid leukemia K562 cells and induce apoptosis.
    • $122
    In Stock
    Size
    QTY
    TargetMol | Inhibitor Sale
  • SIAIS178
    T129072376047-73-1
    SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).
    • $166
    Backorder
    Size
    QTY
    TargetMol | Inhibitor Sale
  • SIAIS100 TFA
    T77969
    SIAIS100 TFA is a potent BCR-ABL PROTAC degrader, exhibiting a DC50 of 2.7 nM. It is utilized in the research of chronic myeloid leukemia (CML) [1].
    • Inquiry Price
    Size
    QTY
  • ON 146040
    T123101404231-34-0
    ON 146040 is an effective inhibitor of PI3K isoforms with IC50s of 14 and 20 nM for PI3Kα and PI3Kδ, respectively.
    • $97
    In Stock
    Size
    QTY
  • ZM 306416
    T1754690206-97-4
    ZM 306416 (CB 676475), a VEGFR1 inhibitor (IC50: 0.33 μM), can also inhibit EGFR (IC50<10 nM).
    • $39
    In Stock
    Size
    QTY
  • Bosutinib hydrate
    T63875918639-08-4
    Bosutinib hydrate (SKI-606 hydrate) is an orally active and potent dual kinase inhibitor of BCR-ABL and Src tyrosine kinases for the study of Philadelphia Chromosome Positive Chronic Granulocytic Leukemia.
    • $33
    In Stock
    Size
    QTY
  • PD173955
    T3063260415-63-2
    PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC.
    • $40
    In Stock
    Size
    QTY
  • Dasatinib hydrochloride
    T22303854001-07-3
    Dasatinib hydrochloride (BMS-354825 HCl) (BMS-354825) hydrochloride is a highly potent, ATP competitive, orally active dual Src/Bcr-Abl inhibitor with potent antitumor activity. The Kis are 16 pM and 30 pM for Src and Bcr-Abl, respectively. Dasatinib hydrochloride hydrochloride inhibits Bcr-Abl and Src with IC50s of <1.0 nM and 0.5 nM, respectively. Dasatinib hydrochloride hydrochloride also induces Apoptosis and Autophagy.
    • $38
    In Stock
    Size
    QTY
  • N-Desmethyl imatinib
    T11641404844-02-6
    N-Desmethyl imatinib (Imatinib metabolite N-Desmethyl imatinib) is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.
    • $84
    In Stock
    Size
    QTY
  • PD180970
    T23128287204-45-9
    PD180970 is an inhibitor of Bcr-Abl with IC50s of 5 nM, 0.8 nM and 50 nM for the autophosphorylation of p210Bcr-Abl, Src and Kit. PD180970 can be used in studies about chronic myelogenous leukemia.
    • $53
    In Stock
    Size
    QTY
  • AEE788
    T2116497839-62-0
    AEE788 (NVP-AEE 788) has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
    • $39
    In Stock
    Size
    QTY
  • Gypsogenin
    T25476639-14-5
    Gypsogenin (639-14-5) is a naturally occurring biochemical that shows anti-ABL1 kinase and anti-chronic Myelogenous Leukemia activities.
    • $136
    In Stock
    Size
    QTY
  • Radotinib
    T2328926037-48-1
    Radotinib (IY-5511), and sometimes referred to by its investigational name IY5511, is a drug for the treatment of different types of Y, most notably Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) with resistance or intolerance of other tyrosine kinase Bcr-Abl inhibitors
    • $39
    In Stock
    Size
    QTY
  • CZC-8004
    T7186916603-07-1
    CZC-8004 (CZC-00008004) is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.
    • $40
    In Stock
    Size
    QTY